Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Buys Protez, Antibiotics Developer
June 9, 2008
| A version of this story appeared in
Volume 86, Issue 23
Novartis has agreed to acquire Protez Pharmaceuticals, a Malvern, Pa.-based firm that is developing PZ-601, a new antibiotic in a class of agents known as carbapenems. According to Novartis, PZ-601 may be better than existing antibiotics against pernicious bacteria strains, including methicillin-resistant Staphylococcus aureus. Novartis is paying $100 million for Protez and could pay its owners another $300 million depending on the success of the drug, which is now in Phase II clinical trials.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter